Oliver Sol
Chief Tech/Sci/R&D Officer chez AC IMMUNE SA
Profil
Oliver Sol is currently working as the VP & Head-Clinical Development at AC Immune SA. Previously, he worked as the Clinical Director at Exonhit and as the Director-Medical & Regulatory Affairs at Eurobio-Scientific SA. Dr. Sol holds a doctorate degree from Université de Paris XI Paris Sud.
Postes actifs de Oliver Sol
Sociétés | Poste | Début |
---|---|---|
AC IMMUNE SA | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Oliver Sol
Sociétés | Poste | Fin |
---|---|---|
EUROBIO SCIENTIFIC | Chief Tech/Sci/R&D Officer | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - |
Formation de Oliver Sol
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AC IMMUNE SA | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
Entreprise privées | 2 |
---|---|
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Université de Paris XI Paris Sud | Consumer Services |